Successful transitions from siloed financial systems require clinical operations, finance, and IT to collaboratively recognize interconnected process issues. This shared urgency and a willingness to abandon "we've always done it this way" mentalities are the true indicators of an organization's readiness for change.

A COVID-19 trial struggled for patients because its sign-up form had 400 questions; the only person who could edit the PHP file was a grad student. This illustrates how tiny, absurd operational inefficiencies, trapped in silos, can accumulate and severely hinder massive, capital-intensive research projects.

The pharmaceutical industry's historically high profitability created a lack of urgency for technological innovation beyond basic ERP systems. It wasn't until patent cliffs and messy M&A integrations squeezed margins that companies began seriously investing in modern data platforms and cloud infrastructure to improve efficiency.

Legacy PBMs run on rigid, antiquated systems like COBOL, inhibiting their ability to find dynamic cost-saving pathways. SmithRx's modern, distributed architecture connects to new low-cost options (like Mark Cuban Cost Plus) and leverages AI to lower its own service costs, creating a dual advantage.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

A primary barrier to modernizing healthcare is that its core technology, the Electronic Health Record (EHR), is often built on archaic foundations from the 1960s-80s. This makes building modern user experiences incredibly difficult.

Despite a threefold increase in data collection over the last decade, the methods for cleaning and reconciling that data remain antiquated. Teams apply old, manual techniques to massive new datasets, creating major inefficiencies. The solution lies in applying automation and modern technology to data quality control, rather than throwing more people at the problem.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Modernizing trials is less about new tools and more about adopting a risk-proportional mindset, as outlined in ICH E6(R3) guidelines. This involves focusing rigorous oversight on critical data and processes while applying lighter, more automated checks elsewhere, breaking the industry's habit of treating all data with the same level of manual scrutiny.